Irhythm unveils new real-world data at acc.25 demonstrating the benefits of zio® long-term continuous monitoring for arrhythmia detection

San francisco, march 31, 2025 (globe newswire) -- irhythm technologies, inc. (nasdaq:irtc) today announced results from two large real-world retrospective analyses presented at the american college of cardiology (acc) 2025 scientific sessions in chicago, il. drawing on data from more than 1.1 million patients who used irhythm's zio® long-term continuous monitoring (ltcm) ecg devices, these studies demonstrate that short-term (24–48-hour) monitoring, such as with holter devices, fails to detect a significant proportion of actionable arrhythmias—even in patients reporting “daily symptoms”—and that symptom–rhythm correlation (src) is notably low for most arrhythmias, underscoring that selection of monitoring duration based on the frequency of symptoms alone can lead to undetected (missed) actionable1 arrhythmias.
ACC Ratings Summary
ACC Quant Ranking